39th Annual J.P.Morgan Healthcare Conference. Vectura CEO Presentation: 8.20 am ET / 13.20 GMT on Thursday 14th January

Executing on our inhaled specialist CDMO strategy

Will Downie, Chief Executive Officer

39th Annual J.P. Morgan Healthcare Conference

14th January 2021

Disclaimer

This presentation has been organised by Vectura Group plc (the Company) in order to provide general information on the Company. This material has been prepared solely by the Company and is (i) for your private information, and the Company is not soliciting any action based upon it (ii) not to be construed as an offer to sell or issue or a solicitation of an offer to buy or subscribe for any security and (iii) based upon information that the Company considers reliable. The Company does not represent that the information contained in this material is accurate or complete, and it should not be relied upon as such. No representation, warranty or undertaking, express or implied, is or will be made with respect to the fairness, accuracy or completeness of any of the information or statement of opinion or expectation contained herein or stated in the presentation or any other such information nor shall you be entitled to rely upon it. In furnishing you with this information no obligation is undertaken to provide you with any further information, to update this information nor any other information nor to correct any information contained herein or any omission therefrom.

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Act"), and may not be offered or sold in the United States or to U.S. persons unless they have been registered under such Act, or except in compliance with an exemption from or in a transaction not subject to the registration requirements of such Act. This presentation has not been approved or disapproved by the US Securities and Exchange Commission, any state securities commission in the United States or any other regulatory authority in the United States, nor have any of the foregoing authorities considered the accuracy or adequacy of the information contained in this material. Any representation to the contrary is a criminal offence in the United States. This material does not constitute or form part of any offer or invitation to sell or issue or any solicitation of an offer to acquire, purchase or subscribe for the Company's securities in any jurisdiction.

No part of this material may be (i) copied, photocopied, or duplicated in any form, by any means, or (ii) redistributed, published, or disclosed by recipients to any other person, in each case without the Company's prior written consent. This material is only being provided to persons who are authorised persons or exempted persons within the meaning of the Financial Services and Markets Act 2000 or any order made thereunder or to other persons of a kind described in Articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005, who are "qualified institutional buyers" as defined in Rule 144 under the Act or institutional "accredited investors" as defined in Rule 501 of Regulation D under the Act, or who are otherwise permitted by law to receive it. In relation to information about the price at which securities in the Company have been bought or sold in the past, note that past performance cannot be relied upon as a guide to future performance. In addition, certain statements, beliefs and opinions in this document, are forward looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward looking statements . These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans

and events described herein. The occurrence of some of the events described in this document and the presentation that will be made, and the achievement of the intended results, are subject to the future occurrence of many events, some or all of which are not predictable or within the Company's control; therefore, actual results may differ materially from those anticipated in any forward looking statements. The Company disclaims any obligation to update these forward looking statements.

By attending the presentationJamesto whichWardthis document-Lilleyrelates or by accepting this document you will be taken to have represented, warranted and undertaken that: (i) you are a person falling within one or more of the categories referred to aboveChiefas beingExecutivepermitted to receiveOfficerthis presentation (ii) you have read and agree to comply with the contents of this disclaimer notice; and (iii) you will not at any time have any discussion, correspondence or contact concerning the information in this document with any of the directors or employees of the Company, its subsidiaries nor with any of their suppliers, customers, sub contractors or any governmental or regulatory body without the prior written consent of the Company.

All references to expected or actual financial information for the year ended 2020 and beyond are stated on a pre-closing and unaudited basis and may be subject to change.

2

WHO WE ARE

Cash generative business with over 20 years' experience in inhaled product development

Established

1997

spin-out from Bath University

Pre-clinical Clinical

development development

Development

£11.4m

Royalties2	2019 Revenues
£51.9m	£178.3m
	+11.1%

Product supply

£115.0m

Commercial manufacture

2019 Revenue

£178.3m

+11% versus 2018

2019 Adj. EBITDA1

£43.4m

+11% versus 2018

2020 Cash balance

£79m

31 Dec 2019: £74.1m

UK listed

FTSE250

constituent company

Widely used technology

13

inhaled products on the market utilising Vectura's IP

Global patients

10m+

using products utilising Vectura's IP in 20203

Employees

~450

• Adjusted EBITDA: Reported operating profit/(loss), adjusted by adding back depreciation, amortisation, impairment, share based compensation, and exceptional items
  2 Royalties comprise royalties, sales-based milestones, and product approval and launch milestones 3 Evaluate Pharma, internal estimates
  FY2020 figures quoted on a pre-close unaudited basis

3

WHAT WE DO

Providing inhaled drug delivery solutions that help our customers bring their medicines to patients

Drug delivery solutions

Molecules

Inhaled medicines

	Formulation		Device platforms
	Proven formulation		Proprietary devices and
	capability		development capability: DPIs,
			pMDIs & nebulisers
Complex drug	Device design	Full pharmaceutical	Device scale-up	Technology transfer
device selection	& development	development	& industrialisation	& manufacture

4